Table 4.

Comparison of clinical and pubertal features by GH-therapy in the studied RASopathy cohort.

PARAMETERS	GH-treated patients (23 pts) Median [IQR]	Untreated GH patients (5 pts) Median [IQR]	p-value
Age at 1st evaluation (yrs)	5.26 [3.09, 9.25]	6.09 [4.85, 7.66]	0.976
Height at 1st evaluation SDS	-2.9 [-3.5, -2.1]	-1.2 [-2.0, -0.4]	0.032
Age at PHV (yrs)	14.2 [12.6, 15.4]	13.4 [12.7-13.9]	0.529
Height at PHV (cm)	145.9 [141.1-154.1]	152.2 [135.6-154.4]	0.787
Spurt duration (yrs)	6.2 [5.4, 7.3]	8.1 [3.8-9.6]	0.407
Spurt gain (cm)	21.5 [15.7, 25.4]	25.7 [16.9-33.4]	0.286
Final height (cm)	157.8 [148.5-165.8]	159.9 [154.4-164.0]	0.653
Final height SDS	-2.2 [-2.6, -1.5]	-1.7 [-2.3, -0.7]	0.286
Target height (cm)	166.5 [160.0, 171.0]	161.75 [158.0-167.5]	0.417
Pubertal timing, n (%)			0.118 ^
◼ normal	15 (71.4%)	3 (60.0%)
◼ delayed onset	5 (23.8%)	0
◼ delayed completion	1 (4.8%)	2 (40.0%)

GH, growth hormone; pts, patients; PHV, peak of height velocity, yrs, years.

Mann-Whitney test except ^ (Fisher’s exact test).